We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Molecular Assay System Validated for Opportunistic Virus Infections

By LabMedica International staff writers
Posted on 31 Oct 2012
Laboratory-developed real-time polymerase chain reaction (PCR) protocols have been implemented for the molecular diagnosis of opportunistic DNA virus infections. More...


The validity of a duplex real-time PCR protocols for viral DNA have been improved by using an extraction and amplification control that allows for the monitoring of the molecular diagnostic process.

Virologists at the Pierre and Marie Curie University (Paris, France) tested 152 clinical samples including 77 whole bloods, 30 bronchoalveolar lavages, 28 viral transport medium containing mucocutaneous swabs, 12 urine, and 5 stool samples. The genomes of herpes simplex virus (HSV), varicella-zoster virus (VZV), human cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK virus (BKV), and adenovirus (AdV) were investigated.

The Simplexa extraction and amplification control (SEAC) set (Eurobio; Courtaboeuf, France) was evaluated in this study. This internal control corresponds to a 577-base pair DNA fragment derived from the gene encoding ribulose-1,5-bisphosphate carboxylase oxygenase large unit N-methyltransferase of the plant Arabidopsis thaliana. This is a noncompetitive internal control with its own mix, containing primers and a Quasar 670 labeled-probe specifically designed for its amplification (Biosearch Technologies; Novato, CA, USA). Viral DNA amplifications were performed on the Light cycler LC480 system (Roche Diagnostics; Meylan, France) using laboratory-developed real-time PCR assays based on hydrolysis probe technology implemented in the laboratory for virological diagnosis activity.

The SEAC results showed high reproducibility with a mean crossing point (Cp) value of 31.08 ± 1.44, and were not influenced by the virus-specific PCR performed or the type of clinical specimen tested. The use of the SEAC did not influence the results of the different virus-specific PCRs compared to other systems. The SEAC in the DNA extracts showed high stability during storage at both +4 °C and -20 °C.

The authors concluded that the use of the commercial SEAC is simple, straightforward, and beneficial. It makes not only the detection of opportunistic viruses in clinical samples more convenient and cost-effective, but it ensures also the effectiveness of the whole molecular process implemented in the laboratory to perform the diagnosis of viral infections. The SEAC provides a reliable option to improve the diagnosis of opportunistic viral infections in laboratories using in-house real-time PCR assays. The study was published in the October 2012 edition of the Journal of Virological Methods.

Related Links:
Pierre and Marie Curie University
Eurobio
Biosearch Technologies


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.